Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 9/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30856724 | 0.87 | RBP4 (0.43) | RBP4IDO1TDO2TRPV1 | |
| SCHEMBL27196762 | 0.87 | RBP4 (0.43) | RBP4IDO1TDO2TRPV1 | |
| SCHEMBL30856723 | 0.85 | RBP4 (0.41) | RBP4IDO1TDO2TRPV1 | |
| SCHEMBL30856720 | 0.84 | RBP4 (0.40) | RBP4IDO1TDO2TRPV1 | |
| SCHEMBL27196773 | 0.84 | RBP4 (0.40) | RBP4IDO1TDO2TRPV1 | |
| SCHEMBL29598313 | 0.81 | RBP4 (0.63) | RBP4 | |
| SCHEMBL17505284 | 0.81 | RBP4 (0.63) | RBP4 | |
| SCHEMBL30857471 | 0.78 | RBP4 (0.54) | NAMPTRBP4 | |
| SCHEMBL29961897 | 0.75 | SSTR4 (0.42) | RBP4 | |
| SCHEMBL20744282 | 0.75 | RBP4 (0.48) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-12-18 | — | — | US | disclosed |
| US-12172987-B2 | Nitrogen-containing saturated heterocyclyl derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-24 | — | — | US | disclosed |
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | NAMPT 3599/4885RBP4 3913/4885IDO1 2884/4885 |
| US-12172987-B2 | Nitrogen-containing saturated heterocyclyl derivative | H1-0, HTT, PRNP | NAMPT 3599/4885RBP4 3913/4885IDO1 2884/4885 |
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | NAMPT 3599/4885RBP4 3913/4885IDO1 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.